Who is sponsoring NCT02247310?

NCT02247310 is sponsored by Bayer.

What drugs are being tested in NCT02247310?

Interventions in NCT02247310: Interferon beta-1b (Betaferon®, BAY 86-5046), BETACONNECT.

What condition does NCT02247310 study?

NCT02247310 studies Multiple Sclerosis, Relapsing Remitting.

Is NCT02247310 still recruiting?

NCT02247310 is currently completed. Last updated 7 November 2017.

Last reviewed 2017-11-07 · How we verify

NCT02247310

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

Completed Last updated 7 November 2017

What this trial tests

trial testing Interferon beta-1b (Betaferon®, BAY 86-5046) in Multiple Sclerosis, Relapsing Remitting in 498 participants. Completed in 8 November 2016.

Timeline

20 October 2014

Primary endpoint
19 July 2016

8 November 2016

Quick facts

Lead sponsor	Bayer
Status	Completed
Study type	OBSERVATIONAL
Enrollment	498
Start date	20 October 2014
Primary completion	19 July 2016
Estimated completion	8 November 2016
Sites	11 locations across Bosnia and Herzegovina, France, Italy, Greece, Belgium, Austria, Hungary, Switzerland

Drugs / interventions tested

Interferon beta-1b (Betaferon®, BAY 86-5046)
BETACONNECT

Conditions studied

Multiple Sclerosis, Relapsing Remitting — all drugs for Multiple Sclerosis, Relapsing Remitting →

Sponsor

Bayer — full company profile →

Who can join

Eligibility, any sex, with Multiple Sclerosis, Relapsing Remitting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Considering the significance of an early and consequent Multiple Sclerosis (MS) treatment as well as the challenge to achieve high adherence to treatment, evaluating the benefits of any new measure to improve adherence is important. The data storage capabilities of the BETACONNECT device, including the automated recording of injections, will facilitate the collection of reliable data on patient's injection behavior and adherence, which should be unaffected by recall bias or reporting bias. To better understand the utilities of the new BETACONNECT device and characterize its contribution to adherence, we plan to prospectively follow-up MS patients using this device for 24 weeks. The study will take place in a real-life setting in Neurology centers across Europe.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT<sup>®</sup> Autoinjector: A Retrospective Cohort Study.
Butler O, Heeg S, Holl K, Frenz AK, et al · · 2021 · cited 2× · PMID 33928518 · DOI 10.1007/s40801-021-00248-5

Verify or expand the search:

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02247310 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 7 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02247310.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing